Psychstocks believes there is only one publicly traded company that is well-positioned to capitalize on rapidly growing interest in DMT and Ayahuasca: Entheon Biomedical (CSE: ENBI), which also trades on the U.S. OTC under the symbol ENTBF.
BetterLife Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD
BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!
On the afternoon of December 18th, Psychstocks announced BetterLife Pharma (CSE: BETR) at $1.17 per share as its #1 favorite Psychstock for 2021. BETR closed today at its high of day of $2.25 per share. BETR has already gained by 92.3% in only seven trading days!
BETR is truly establishing the best possible team to take LSD and other psychedelics from experimental to major therapeutic applications.
Numinus Wellness (TSXV: NUMI) gained as much as 9.87% today to hit a new all-time high of $2.45 per share for a gain of 807.41% since we profiled it as our #1 favorite Psychstock at $0.27 per share!
Psychstocks founder Gerard Adams considers RVV and NUMI to be the two highest quality small-cap stocks in the psychedelic space and their incredibly strong performance is proving Gerard right!
NUMI is pleased about first-of-its-kind policy amendment that will allow legal access to evidence-based treatments to those in need before formal drug approval.
Numinus Wellness (TSXV: NUMI) had its biggest up day in history on Wednesday gaining by 34.83% to finish at a new all-time high closing price of $1.20 per share.
NUMI and MAPS Public Benefit Corporation Announce Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD
This is perhaps NUMI’s most significant development in its history.
Psychedelics industry bellwether Compass Pathways (CMPS) gained $6.62 or 16.21% today to finish at a new all-time high closing price of $47.45 per share! We consider Revive Therapeutics (CSE: RVV) to be the #1 highest quality small-cap psychedelic biotech play.
RVV provides important update on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison.
Oregon residents voted to pass Measure 109 to legalize psilocybin from mushrooms while Washington DC residents voted to pass Initiative 81 to decriminalize natural plant medicines.
NUMI has just made history by harvesting the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence.